Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Acerta Pharma BV
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02296918CT.gov Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | — | Completed | — | — | — |
NCT02029443CT.gov ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02007044CT.gov Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01076556CT.gov Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — | Terminated | — | — | — |
NCT00612612CT.gov Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | — | Terminated | — | — | — |
NCT00098488CT.gov 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prolymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | Acerta Pharma BV | P2 | B · 63 |
| Cyclophosphamide | Center for International Blood and Marrow Transplant Research | P2 | BBB |
| Fludarabine | Center for International Blood and Marrow Transplant Research | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Nivestim | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Tacrolimus | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Busulfanum | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Melphalan | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Ibrutinib | Fred Hutchinson Cancer Center | P2 | B |
+42 more in the Prolymphocytic Leukemia cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideCenter for International Blood and Marrow Transplant ResearchBBB
- FludarabineCenter for International Blood and Marrow Transplant ResearchBB
- Cyclosporin AFred Hutchinson Cancer CenterBB
- NivestimCenter for International Blood and Marrow Transplant ResearchBB
- TacrolimusCenter for International Blood and Marrow Transplant ResearchBB
Citation
Floatz Terminal. Rituximab in Prolymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-prolymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →